Intellia’s CRISPR Submission Is a Regulatory Stress Test the FDA Has Never Faced Before

Picture a regulatory affairs team at Intellia Therapeutics opening the FDA’s September 2024 draft guidance on postapproval methods for cell and gene therapy products and searching for the section that addresses permanent, single-dose genomic edits in 60,000 base pairs of a living patient’s hepatocytes. They will not find it. The guidance is thoughtful, carefully constructed, and almost entirely written for a world that existed before nexiguran ziclumeran — nex-z, formerly NTLA-2001 — became the first in vivo CRISPR-based gene editing therapy headed to FDA review. That gap between the framework on paper and the therapy now sitting in front of reviewers defines everything at stake in this submission.

Nex-z targets transthyretin amyloidosis (ATTR), a progressive and frequently fatal disease caused by misfolded TTR protein deposits in peripheral nerves and the heart. The therapy uses lipid nanoparticles to deliver CRISPR-Cas9 machinery directly into hepatocytes, editing the TTR gene in vivo and permanently reducing circulating TTR protein. The FDA granted nex-z Regenerative Medicine Advanced Therapy designation on November 25, 2024, and cleared the IND on November 7, 2024 — signals of serious engagement. But RMAT designation and IND clearance are not approval. They are an invitation to a conversation the agency has never fully had before.

The conventional assumption in gene therapy circles is that FDA review experience with AAV vectors and ex vivo cell therapies gives the agency a sufficient template for evaluating in vivo CRISPR. That assumption deserves direct challenge.

Why the Old Playbook Doesn’t Fit

Consider what RMAT designation and prior CRISPR IND experience actually represent. Editas Medicine’s EDIT-101 — an in vivo CRISPR therapy for Leber Congenital Amaurosis type 10, delivered subretinally — received FDA IND acceptance on November 30, 2018, marking it as the first in vivo CRISPR medicine cleared for human administration in the United States. That was a locally delivered edit in a post-mitotic tissue. Nex-z delivers systemically, targeting the liver at scale. The biological exposure profile, the off-target risk surface, and the durability assumptions are categorically different — and the regulatory precedent from EDIT-101 carries only so far.

Verve Therapeutics learned this the hard way. The company’s VERVE-101, a base-editing therapy targeting PCSK9 for cardiovascular disease, encountered a clinical hold after its Heart-1 trial reported a serious adverse event, forcing a pause and redesign of safety monitoring protocols. Base editing and CRISPR-Cas9 are distinct mechanisms, but they share the fundamental challenge: once the edit is made in hepatocytes, you cannot recall it. The liver’s regenerative capacity means edited cells can replicate, potentially expanding the population of modified hepatocytes beyond what the initial delivery achieved. No one fully knows the fifty-year pharmacodynamic profile of a TTR gene edit delivered at age 52.

That durability problem is precisely where the FDA’s existing guidance architecture shows its seams. The agency’s 2024 draft guidance on postapproval CGT surveillance recommends long-term follow-up registries and real-world data capture — sound in principle, but built around a product lifecycle model where the sponsor controls ongoing therapy. With nex-z, Intellia administers the therapy once. The edit persists. The patient then lives with a permanent genomic modification through decades of care transitions, insurer changes, EHR system migrations, and potential loss to follow-up. The guidance recommends these patients be monitored; it does not specify how you maintain a registry cohort for 15 years when the therapy requires no refills, no infusion visits, and no ongoing commercial relationship to anchor the follow-up structure.

Which raises an uncomfortable operational question: who pays for that follow-up, and what protocol deviation framework governs it?

The Protocol Architecture Problem

The FDA’s draft guidance on protocol deviations — addressed through WCG Clinical’s analysis of the agency’s recommendations — establishes that sponsors, investigators, and IRBs share responsibility for defining, identifying, and reporting deviations in clinical investigations of drugs and biologics. In a conventional Phase 3 trial, a missed visit at month 18 is a protocol deviation with clear remediation steps. In an in vivo CRISPR trial, a missed safety biomarker draw at year 7 post-edit is a data gap with no remediation available — the exposure event is permanent and years past, the off-target editing signal either captured then or lost forever.

This creates a monitoring architecture that trial sponsors are largely inventing in real time. The clinical team running the nex-z program cannot look at a prior BLA for a permanent genomic editor in hepatocytes and borrow their DSMB charter. There is no prior BLA. In February 2025, a personalized in vivo CRISPR 2.0 base editing treatment using an adenosine base editor (K-abe) was administered to an infant identified as KJ, with a defective CPS1 gene — a heroic and scientifically remarkable intervention, but a single compassionate-use case, not a regulatory blueprint. Intellia’s team is writing the template as they submit it.

The safety signal detection problem is equally underappreciated. Off-target editing in hepatocytes could, in theory, disrupt oncogene suppressor regions. The latency between an off-target edit and a detectable hepatocellular signal could span a decade. No current long-term follow-up framework is built to capture that signal with statistical power against background hepatocellular carcinoma rates in an aging ATTR patient population — a population already at elevated baseline risk from their underlying disease and its treatments.

The FDA’s reviewers know this. The question is whether the BLA review division will accept probabilistic safety arguments backed by preclinical off-target sequencing data, or whether they will require prospective long-term follow-up commitments so extensive that they functionally delay approval by demanding infrastructure that does not yet exist.

What the FDA Must Build, Not Just Review

The real-world evidence capture challenge for durable genetic interventions is one the FDA has acknowledged without fully solving. The agency’s 2024 draft guidance explicitly incorporates real-world data and AI-assisted surveillance methods for postmarket CGT monitoring — a meaningful conceptual advance. But conceptual advance and operational infrastructure are separated by years of implementation work. Intellia cannot wait for the agency to build an AI-powered hepatocellular surveillance registry before receiving a decision on a therapy for patients who are dying of ATTR amyloidosis today.

The irony cuts deep. ATTR amyloidosis has existing approved therapies — patisiran (Alnylam’s RNA interference drug) and tafamidis (Pfizer’s stabilizer) — that require chronic dosing. Patisiran costs approximately $450,000 per year. Tafamidis runs roughly $225,000 annually. A one-time gene edit that achieves durable TTR knockdown could, in theory, be cost-superior over a ten-year horizon even at a price point above $1 million. The economic argument for approval is clear. The regulatory science argument for a framework that can actually monitor what happens after approval is the harder problem — and it belongs to the FDA to solve, not just to Intellia to propose.

The agency has an opportunity here that it rarely gets: to build review standards for in vivo CRISPR therapies before the field scales, not after five approvals and three post-market safety signals force a reactive reckoning. The Intellia BLA is not just a single product review. It is the first draft of a regulatory architecture that will govern every permanent genomic editor that follows it — and the agency’s response will set the evidentiary floor for an entire modality. Whether the FDA treats this as a standard CGT review or as the category-defining moment it actually is will determine whether sponsors building the next generation of in vivo editors have a coherent path forward, or spend the next decade in a cycle of Type B meetings that never quite resolve the same unanswered questions about durability, off-target risk, and long-term follow-up obligations.

The edit, once made, cannot be undone. The regulatory standard set here will be equally permanent.

References

1. Nature Biotechnology — “Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy”
2. Intellia Therapeutics / GlobeNewswire — “FDA Grants RMAT Designation and Clears IND for Nexiguran Ziclumeran (nex-z), Q3 2024 Financial Results”
3. FDA — “Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products; Draft Guidance for Industry” (September 2024)
4. Editas Medicine / GlobeNewswire — “FDA Acceptance of IND Application for EDIT-101” (November 30, 2018)
5. Eric Topol / Ground Truths — “The First Human to Undergo In Vivo CRISPR 2.0 Gene Editing” (February 2025)
6. First Word Pharma — “Verve Therapeutics VERVE-101 Heart-1 Trial Safety Event”
7. BioPharm International — “New FDA Guidance Utilizes Real-World Data and AI for Postmarket CGT Surveillance”
8. WCG Clinical — “Protocol Deviations Explained: Understanding the FDA’s Draft Guidance”
9. PMC / NIH — “NTLA-2001 (Nexiguran Ziclumeran) for Transthyretin Amyloidosis: Safety and Efficacy Data”